Biological Significance of ¹⁸F-FDG PET/CT Maximum Standard Uptake Value for Predicting EGFR Mutation Status in Non-Small Cell Lung Cancer Patients

References

• Ujiie H, Yasufuku K. The importance of novel molecular biomarker of early stage lung adenocarcinoma. Transl Cancer Res. 2017;6:S964–S968. doi:10.21037/tcr.2017.06.12
   Web of Science ®Google Scholar
• Cadranel J, Ruppert AM, Beau-Faller M, Wislez M. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. Crit Rev Oncol Hematol. 2013;88(3):477–493. doi:10.1016/j.critrevonc.2013.06.009
   PubMed Web of Science ®Google Scholar
• Patel N, Wu P, Zhang H. Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation. Cancer Manag Res. 2017;9:243–248. doi:10.2147/CMAR.S138643
   PubMed Web of Science ®Google Scholar
• Liu Y, Kim J, Qu F, et al. CT features associated with epidermal growth factor receptor mutation status in patients with lung adenocarcinoma. Radiol. 2016;280(1):271–280. doi:10.1148/radiol.2016151455
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Sakai F, Ishikawa R, Kimura F, Ishida H, Kobayashi K. CT features of epidermal growth factor receptor–mutated adenocarcinoma of the lung: comparison with nonmutated adenocarcinoma. J Thorac Oncol. 2016;11(6):819–826. doi:10.1016/j.jtho.2016.02.010
   PubMed Web of Science ®Google Scholar
• Dai J, Shi J, Soodeen-Lalloo AK, et al. Air bronchogram: a potential indicator of epidermal growth factor receptor mutation in pulmonary subsolid nodules. Lung Cancer. 2016;98:22–28. doi:10.1016/j.lungcan.2016.05.009
   PubMed Web of Science ®Google Scholar
• Cheng Z, Shan F, Yang Y, Shi Y, Zhang Z. CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis. BMC Med Imaging. 2017;17(1):5. doi:10.1186/s12880-016-0175-3
   PubMed Web of Science ®Google Scholar
• Pauwels EK, Coumou AW, Kostkiewicz M, Kairemo K. [(1)(8)F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography imaging in oncology: initial staging and evaluation of cancer therapy. Med Princ Pract. 2013;22(5):427–437. doi:10.1159/000346303
   PubMed Web of Science ®Google Scholar
• Wang H, Li J, Chen F, et al. Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumours. Eur Radiol. 2010;20(8):2013–2026. doi:10.1007/s00330-010-1743-5
   PubMed Web of Science ®Google Scholar
• Gandhi J, Zhang J, Xie Y, et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One. 2009;4(2):e4576. doi:10.1371/journal.pone.0004576
   PubMed Web of Science ®Google Scholar
• Putora PM, Fruh M, Muller J. FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma. Respirology. 2013;18(4):734–735. doi:10.1111/resp.12083
   PubMed Web of Science ®Google Scholar
• Lee SM, Bae SK, Jung SJ, Kim CK. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients. Clin Nucl Med. 2015;40(12):950–958. doi:10.1097/RLU.0000000000000975
   PubMed Web of Science ®Google Scholar
• Na II, Byun BH, Kim KM, et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer. 2010;67(1):76–80. doi:10.1016/j.lungcan.2009.03.010
   PubMed Web of Science ®Google Scholar
• Guan J, Xiao NJ, Chen M, et al. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer. Medicine. 2016;95(30):e4421. doi:10.1097/MD.0000000000004421
   PubMed Web of Science ®Google Scholar
• Cho A, Hur J, Moon YW, et al. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer. BMC Cancer. 2016;16:224. doi:10.1186/s12885-016-2251-z
   PubMed Web of Science ®Google Scholar
• Takamochi K, Mogushi K, Kawaji H, et al. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma. PLoS One. 2017;12(4):e0175622. doi:10.1371/journal.pone.0175622
   PubMed Web of Science ®Google Scholar
• Lv Z, Fan J, Xu J, et al. Value of (18)F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients. Eur J Nucl Med Mol I. 2018;45(5):735–750. doi:10.1007/s00259-017-3885-z
   PubMed Web of Science ®Google Scholar
• Gao X-C, Wei C-H, Zhang R-G, et al. 18 F-FDG PET/CT SUV max and serum CEA levels as predictors for EGFR mutation state in Chinese patients with non-small cell lung cancer. Oncol Lett. 2020;20(4):61. doi:10.3892/ol.2020.11922
   PubMed Web of Science ®Google Scholar
• Zhu L, Yin G, Chen W, et al. Correlation between EGFR mutation status and F18-fluorodeoxyglucose positron emission tomography-computed tomography image features in lung adenocarcinoma. Thoracic Cancer. 2019;10(4):659–664. doi:10.1111/1759-7714.12981
   PubMed Web of Science ®Google Scholar
• Huang CT, Yen RF, Cheng MF, et al. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol. 2010;27(1):9–15. doi:10.1007/s12032-008-9160-1
   PubMed Web of Science ®Google Scholar
• Ko KH, Hsu HH, Huang TW, et al. Value of (1)(8)F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. Eur J Nucl Med Mol I. 2014;41(10):1889–1897. doi:10.1007/s00259-014-2802-y
   PubMed Web of Science ®Google Scholar
• Kanmaz ZD, Aras G, Tuncay E, et al. Contribution of (1)(8)Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma. Cancer Biomark. 2016;16(3):489–498. doi:10.3233/CBM-160588
   PubMed Web of Science ®Google Scholar
• Wang Q, Mou J, Yang X, et al. EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers? Lung Cancer. 2013;4:27–33.
   PubMedGoogle Scholar
• Chong GO, Lee YH, Hong DG, Cho YL, Lee YS. Unabsorbed polylactide adhesion barrier mimicking recurrence of gynecologic malignant diseases with increased 18F-FDG uptake on PET/CT. Arch Gynecol Obst. 2015;292(1):191–195. doi:10.1007/s00404-014-3587-8
   PubMed Web of Science ®Google Scholar
• Usuda K, Sagawa M, Motono N, et al. Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive? Asian Pac J Cancer Prev. 2014;15(2):657–662. doi:10.7314/APJCP.2014.15.2.657
   PubMedGoogle Scholar
• Lee EYP, Khong P-L, Lee VHF, Qian W, Yu X, Wong MP. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation. Clin Nucl Med. 2015;40(3):e190–e195. doi:10.1097/RLU.0000000000000684
   PubMed Web of Science ®Google Scholar
• Yu C, Xia X, Qin C, Sun X, Zhang Y, Lan X. Is SUVmax helpful in the differential diagnosis of enlarged mediastinal lymph nodes? A pilot study. Contrast Media Mol I. 2018;2018:3417190. doi:10.1155/2018/3417190
   PubMed Web of Science ®Google Scholar
• Kim JH, Nam B, Choi YJ, et al. Enhanced glycolysis supports cell survival in EGFR-mutant lung adenocarcinoma by inhibiting autophagy-mediated EGFR degradation. Cancer Res. 2018;78(16):4482. doi:10.1158/0008-5472.CAN-18-0117
   PubMed Web of Science ®Google Scholar
• Xu W, Yin G, Zhang Y. Predictive power of a radiomic signature based on 18F-FDG PET/CT images for EGFR mutational status in NSCLC. Front Oncol. 2019;9:1062. doi:10.3389/fonc.2019.01062
   PubMed Web of Science ®Google Scholar
• Yip SS, Kim J, Coroller TP, et al. Associations between somatic mutations and metabolic imaging phenotypes in non–small cell lung cancer. J Nucl Med. 2017;58(4):569. doi:10.2967/jnumed.116.181826
   PubMed Web of Science ®Google Scholar